La cadena de opciones muestra datos clave de las opciones de acciones de Akebia Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Akebia Therapeutics..

Akebia Therapeutics (NASDAQ:AKBA) Bolsa, Cadena de Opciones

AKEBIA THERAPEUTICS INC

Akebia Therapeutics

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

Movers_Stocks

AAOI

AFYA

BTBT

CVNA

DOCU

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

MRNA

NTRA

SRDX

TEVA

9 Health Care Stocks Whale Activity In Today's Session

<a href="https://www.globenewswire.com/Tracker?data=vzdj-uBtDE9BfwfY4CNUyIvLcwyvR2fgom87L8iB02gZ160yifipO7kHmup1liDRd-B1JPSV-U4AOqhtt9S2tBO0FS35ROxMrh9H8J9CQW8=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the <a href="https://www.globenewswire.com/Tracker?data=JGOn-OYYoMVTp8heDhWiIuJKGHfmd48rqGv5eHQQ8kc7gAgrlFsj3_GgtDnF9APh7splsiW8lglZawZzHbn8CtJmJNQ5KHBPx0Iwr-01R86W9aI6wSu-probtX_Q0JQcxNJ1KPwxbyJZJlUjlcb_Imk8p1hYV0r6y6MGDMeckBQ=">Journal of the American Society of Nephrology</a> (JASN) has published pre-specified analyses for the U.S. and non-U.S. patient subgroups from the vadadustat global phase 3 clinical program, which included two trials in patients with dialysis-dependent chronic kidney disease (DD-CKD; INNO2VATE) and two trials in patients with non–dialysis-dependent CKD (NDD-CKD; PRO2TECT).
The vadadustat global phase 3 clinical trials were open-label, randomized, noninferiority trials that compared the safety and efficacy of vadadustat with darbepoetin alfa in adult patients with CKD-related anemia. Data from the pre-specified analyses for the U.S. patient subgroup demonstrate that among patients with DD-CKD, safety and efficacy of vadadustat and darbepoetin alfa in the U.S. and outside the U.S. were similar. Among the U.S. patient subgroup with NDD-CKD, safety and efficacy outcomes were similar, but the risk for major adverse cardiovascular event (MACE) with vadadustat was higher than darbepoetin alfa outside the United States. In these analyses, safety was measured by time to first MACE and efficacy was measured by mean change in hemoglobin. The article titled, "Safety and Efficacy of Vadadustat for the Treatment of CKD-Related Anemia within and outside the United States," is available <a href="https://www.globenewswire.com/Tracker?data=Q8EAVRvCjTfUeHUP9KZPv1XrVAofNmL7y37CuUJMd50apQdt2jSxjTuWAeIzImcKumpGwzv_CTAcPULWd7nBmc_JvEHVLGE99uMinZDXcjPFXAhtpm-tPAT2JysrmOo6498dIj5-E-5dobmq0yM9kBl2QtAIexVYRMZFKsZj-ng=">here</a>.
Vafseo&#xAE; (vadadustat) was approved by the U.S. Food and Drug Administration in March 2024 for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. Vafseo has been available in the U.S. since January 2025.

Biotech

News

General

Akebia Therapeutics Announces Publication In JASN Of U.S. And Non-U.S. Subgroup Analyses From Vadadustat Global Phase 3 Trials, Showing Comparable Safety And Efficacy In Dialysis-Dependent CKD Patients And Highlighting Elevated MACE Risk In U.S. Non–Dialysis-Dependent CKD Patients

HC Wainwright &amp; Co. analyst Matthew Caufield assumes Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy rating and announces Price Target of $8.

Price Target

Initiation

Analyst Ratings

HC Wainwright & Co. Assumes Akebia Therapeutics at Buy, Announces Price Target of $8

WIIM

Akebia Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 22.9% to $0.44 during Thursday's pre-market session. The market value of their outstanding shares is at $27.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 18.55% to $5.62. The market value of their outstanding shares is at $305.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock rose 16.37% to $1.35. The market value of their outstanding shares is at $22.3 million. </li>
<li>Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) shares moved upwards by 16.18% to $5.6. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock moved upwards by 12.94% to $6.72. The company's market cap stands at $1.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares increased by 12.6% to $2.77. The company's market cap stands at $723.6 million. As per the press release, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 63.4% to $0.11 during Thursday's pre-market session. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 29.2% to $0.33. The company's market cap stands at $8.2 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) shares fell 14.69% to $5.81. The market value of their outstanding shares is at $41.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares decreased by 13.47% to $5.91. The market value of their outstanding shares is at $106.3 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 13.32% to $0.59. The market value of their outstanding shares is at $2.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 12.5% to $0.01. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AVAH

AXDX

CGTX

ECOR

LGMK

MIRA

NCNA

NVAX

ZVSA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.04) by 175 percent. This is a 133.33 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $57.34 million which beat the analyst consensus estimate of $44.88 million by 27.75 percent. This is a 75.84 percent increase over sales of $32.61 million the same period last year.

Earnings

Earnings Beats

Akebia Therapeutics Q1 EPS $0.03 Beats $(0.04) Estimate, Sales $57.34M Beat $44.88M Estimate

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-08. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Akebia Therapeutics will report an earnings per share (EPS) of $-0.04.
The announcement from Akebia Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 33.73% increase in the share price on the subsequent day.
Here's a look at Akebia Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.10</td>
<td>-0.10</td>
<td>-0.04</td>
<td>-0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>34.0%</td>
<td>4.0%</td>
<td>-7.000000000000001%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630193_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Akebia Therapeutics were trading at $2.32 as of May 06. Over the last 52-week period, shares are up 80.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AKBA/earnings">To track all earnings releases for Akebia Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Akebia Therapeutics's Quarterly Earnings

HC Wainwright &amp; Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy and maintains $7.5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target

<a href="https://www.globenewswire.com/Tracker?data=7l57jPT7AZDn06CKZpFEvCZWIfVofhoCdY1ADg0wIzox9VuZpgQRe1PjoOSmOEVcGBL6lOiOros8Dh9aXF-XJoIVl6t6ZeONjLprU1SgmlU=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL&#xAE; (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. Averoa recently announced the positive opinion from CHMP here: <a href="https://www.globenewswire.com/Tracker?data=YC3k_S4HYmByvgOHZ8KXr9C0l6cq2mm2kfWvZCIPt6Z_Lb_YAZuD_AN4OU8B8GfuKWmJWYc1ze_64nltBee9vEAkzlG0WPcS8tWwIQOgbg6vFL0aZwl9rFqnbqLk1eJ21wf7V3RWjz3kl4lrcqqsJ0FtpBJzHBRGq2fXfRng6WWEcZJcsByl-xY1MSoTfuiY4IfFo9KwQezWnnOVW2ZRKUgDbA9JFoMZh9bfpbTLWnRCZsioMOIoCuyDeRr2FdWMyD4-vYX-cKnW8l08ViedE5-LMOEdXv0Fd-LS6zelN-AJTu2nE1ZtTq8h_35h_TKX">https://averoa-pharma.org/wp-content/uploads/2025/04/20250402-AVA1014-Positive-opinion-EN-VF-2.04.2025.pdf</a>.
"We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe," said John P. Butler, Chief Executive Officer of Akebia.
The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.

Akebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous And Iron Deficiency In Adult Patients With Chronic Kidney Disease

Jefferies analyst Roger Song initiates coverage on Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) with a Buy rating and announces Price Target of $6.

Jefferies Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $6

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 226.4% to $1.73 during Thursday's regular session. The market value of their outstanding shares is at $19.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 205.28% to $1.56. The market value of their outstanding shares is at $9.1 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock moved upwards by 54.63% to $9.28. The company's market cap stands at $93.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock rose 31.36% to $2.22. The company's market cap stands at $1.6 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock moved upwards by 27.84% to $11.98. The company's market cap stands at $98.8 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) stock moved upwards by 26.43% to $14.73. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 38.8% to $0.29 during Thursday's regular session. The company's market cap stands at $17.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 28.51% to $0.32. The market value of their outstanding shares is at $82.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares declined by 28.35% to $2.04. The company's market cap stands at $480.7 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 20.28% to $2.59. The company's market cap stands at $1.7 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares fell 18.76% to $1.43. The market value of their outstanding shares is at $46.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 17.1% to $1.94. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

BDRX

CRVO

ELEV

PSTV

RMTI

SPRY

VERO

WINT

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
The Dow traded up 0.63% to 42,230.78 while the NASDAQ climbed 0.81% to 17,894.89. The S&amp;P 500 also rose, gaining, 0.61% to 5,710.13.
Check This Out: <a href="https://www.benzinga.com/25/03/44414809/tesla-to-450-here-are-10-top-analyst-forecasts-for-thursday">Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday</a>
Leading and Lagging Sectors Communication services shares rose by 1.4% on Thursday.
In trading on Thursday, consumer staples shares fell by 0.1%.
Top Headline
U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) shares shot up 48% to $22.99 after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>Shares of Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>)got a boost, surging 71% to $2.8950 after the company entered a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem&#8217;s PHEXXI.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares were also up, gaining 55% to $9.28 after Paratek Pharmaceuticals announced it will acquire the company in a deal worth $330 million.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Elevation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) shares dropped 41% to $0.2798 after the company announced the discontinued development of EO-3021.</li>
<li>Shares of Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) were down 42% to $0.3755 after the company filed for Chapter 11 bankruptcy.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) was down, falling 30% to $1.9950 after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.</li>
</ul>
Commodities In commodity news, oil traded up 1.3% to $68.00 while gold traded up 0.1% at $3,044.60.
Silver traded down 0.6% to $34.015 on Thursday, while copper fell 0.1% to $5.0930.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.47%, Germany's DAX 40 fell 1.43% and France's CAC 40 fell 0.86%. Spain's IBEX 35 Index fell 0.97%, while London's FTSE 100 slipped 0.15%.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 0.51%, Hong Kong's Hang Seng Index dipped 2.23% and India's BSE Sensex gaining 1.19%.
Economics
<ul>
<li>U.S. existing home sales increased by 4.2% from the previous month to an annualized rate of 4.26 million homes in February.</li>
<li>The U.S. current account deficit shrank by 2.0% to $303.9 billion in the fourth quarter, versus a revised deficit of $310.3 billion in the third quarter.</li>
<li>U.S. initial jobless claims increased by 2,000 to 223,000 during the second week of March, compared to market estimates of 224,000.</li>
<li>The Philadelphia Fed Manufacturing Index fell to 12.5 in March from 18.1 in the previous month, versus market estimates of 8.5.</li>
<li>U.S. natural gas stocks increased 9 billion cubic feet in the week ending March 14, compared to market estimates of a 3 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44415297/how-to-earn-500-a-month-from-micron-technology-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Micron Technology Stock Ahead Of Q2 Earnings</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase

Akebia Therapeutics shares are trading lower after the company announced the pricing of a $50 million offering of 25 million common shares at $2/share.

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.
Shares of JOYY Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/YY/earnings">weak quarterly sales</a>.
JOYY reported quarterly earnings of $1.77 per share which beat the analyst consensus estimate of $1.18 per share. The company reported quarterly sales of $549.45 million which missed the analyst consensus estimate of $549.46 million by 0 percent. This is a 3.58 percent decrease over sales of $569.84 million the same period last year.
JOYY shares dipped 10.9% to $41.75 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 26.2% to $2.09 in pre-market trading after the company priced its $50 million public offering of 25 million common shares at $2 per share.</li>
<li>Maze Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 11.8% to $10.70 in today's pre-market trading.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) declined 7.2% to $11.01 in pre-market trading.</li>
<li>Enerflex Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) fell 7.1% to $7.00 in pre-market trading after the company reported that Marc Rossiter has stepped down as President, CEO, and Director.</li>
<li>ZTO Express (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) declined 5.8% to $20.49 in pre-market trading.</li>
<li>Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) fell 5.5% to $51.54 in pre-market trading after the company announced an offering of $1.35 of billion depository shares.</li>
<li>UP Fintech Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) fell 4.7% to $9.21 in pre-market trading.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 2.5% to $30.00 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: zignal_88 on Shutterstock.com

Pre-Market Outlook

GHRS

MCHP

TIGR

JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) shares moved upwards by 58.3% to $9.5 during Thursday's pre-market session. The market value of their outstanding shares is at $95.5 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 35.5% to $2.29. The company's market cap stands at $1.7 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock rose 20.99% to $0.62. The company's market cap stands at $3.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares moved upwards by 15.56% to $1.63. The company's market cap stands at $3.4 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares rose 13.01% to $0.85. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) stock rose 12.96% to $11.33. The market value of their outstanding shares is at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) stock decreased by 23.9% to $2.16 during Thursday's pre-market session. The market value of their outstanding shares is at $510.2 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares declined by 16.67% to $1.95. The market value of their outstanding shares is at $1.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.32% to $0.29. The company's market cap stands at $7.3 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares decreased by 12.32% to $10.4. The market value of their outstanding shares is at $645.0 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares declined by 9.1% to $1.6. The company's market cap stands at $51.7 million. The company's, Q4 earnings came out today. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.07% to $0.35. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

AEON

MSPR

TNFA

Shares of Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter <a href="https://in.benzinga.com/news/earnings/25/03/44406668/five-below-stock-moves-higher-on-q4-earnings-beat">guidance above estimates</a>.
Five Below reported adjusted earnings of $3.48 per share, beating market estimates of $3.38 per share. The company's sales came in at $1.391 billion versus expectations of $1.386 billion.
Five Below shares jumped 11.9% to $84.59 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>SAG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAG#NASDAQ">SAG</a>) gained 77.8% to $1.20 in pre-market trading after jumping 7% on Wednesday.</li>
<li>OptiNose, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) rose 59.3% to $9.56 in pre-market trading. Paratek Pharmaceuticals announced plans to acquire Optinose in a deal worth up to $330 million.</li>
<li>ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) gained 50.6% to $23.41 in pre-market trading after the company announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) gained 40.3% to $0.1010 in pre-market. AGM Group Holdings announced the receipt of Nasdaq notification regarding minimum bid requirements.</li>
<li>DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) gained 28.7% to $0.4761 in pre-market trading after jumping 8% on Wednesday.</li>
<li>Emerson Radio Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSN#NYSE">MSN</a>) gained 27.2% to $0.56 in pre-market trading.</li>
<li>CIMG Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMG#NYSE">IMG</a>) gained 21.1% to $0.5812 in pre-market trading after the company announced its subsidiary signed a business cooperation intent agreement with Shanghai Huomao.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 12.1% to $1.02 in pre-market trading.</li>
<li>Brookdale Senior Living Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) rose 8.1% to $6.60 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) fell 28.4% to $0.2196 in pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Akebia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 26.2% to $2.09 in pre-market trading after the company priced its $50 million public offering of 25 million common shares at $2 per share.</li>
<li>Leishen Energy Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NYSE">LSE</a>) fell 17.1% to $10.37 in pre-market trading after gaining around 66% on Wednesday. Leishen Energy recently reported FY24 financial results.</li>
<li>Riverview Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSB#NASDAQ">RVSB</a>) declined 13.2% to $4.66 in pre-market trading.</li>
<li>Benson Hill, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NASDAQ">BHIL</a>) dipped 13.2% to $0.56 in pre-market trading after dipping 15% on Wednesday.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares tumbled 13.2% to $0.0944 in pre-market trading. Virpax Pharmaceuticals shares fell 16% on Wednesday after the company announced a 1-for-25 reverse stock split.</li>
<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares fell 12.3% to $0.2884 in pre-market trading.</li>
<li>Maze Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 11.8% to $10.70 in today's pre-market trading.</li>
<li>JOYY Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YY#NASDAQ">YY</a>) shares dipped 10.8% to $41.78 in pre-market trading following weak quarterly sales.</li>
<li>Enerflex Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFXT#NYSE">EFXT</a>) fell 7.1% to $7.00 in pre-market trading after the company reported that Marc Rossiter has stepped down as President, CEO, and Director.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: Shutterstock

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on March 21, 2025, subject to the satisfaction of customary closing conditions

Reported Earlier, Akebia Therapeutics Prices $50M Public Offering Of 25M Common Shares At $2/Share

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Akebia Therapeutics

Akebia Therapeutics (AKBA) Opciones

Akebia Therapeutics (NASDAQ:AKBA) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL